These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 25079474)

  • 1. Looking into the crystal ball-upcoming drugs for dyslipidemia.
    George M; Selvarajan S; Muthukumar R; Elangovan S
    J Cardiovasc Pharmacol Ther; 2015 Jan; 20(1):11-20. PubMed ID: 25079474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid-lowering agents.
    Ewang-Emukowhate M; Wierzbicki AS
    J Cardiovasc Pharmacol Ther; 2013 Sep; 18(5):401-11. PubMed ID: 23811423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?
    Page MM; Hooper AJ; Burnett JR
    Expert Opin Pharmacother; 2016; 17(2):275-81. PubMed ID: 26642232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.
    Kones R; Rumana U
    Drugs; 2015 Jul; 75(11):1201-28. PubMed ID: 26169307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigational therapies for the treatment of atherosclerosis.
    Tomkin GH; Owens D
    Expert Opin Investig Drugs; 2014 Oct; 23(10):1411-21. PubMed ID: 24857672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical review of non-statin treatments for dyslipoproteinemia.
    Pang J; Chan DC; Watts GF
    Expert Rev Cardiovasc Ther; 2014 Mar; 12(3):359-71. PubMed ID: 24506448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel agents to manage dyslipidemias and impact atherosclerosis.
    Nachimuthu S; Raggi P
    Cardiovasc Hematol Disord Drug Targets; 2006 Sep; 6(3):209-17. PubMed ID: 17017903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The treatment of dyslipidemia--what's left in the pipeline?
    Rau O; Zettl H; Popescu L; Steinhilber D; Schubert-Zsilavecz M
    ChemMedChem; 2008 Feb; 3(2):206-21. PubMed ID: 17963209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging antidyslipidemic drugs.
    Pollex RL; Joy TR; Hegele RA
    Expert Opin Emerg Drugs; 2008 Jun; 13(2):363-81. PubMed ID: 18537526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dyslipidemia management update.
    Chang Y; Robidoux J
    Curr Opin Pharmacol; 2017 Apr; 33():47-55. PubMed ID: 28527325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholesteryl ester transfer protein (CETP) deficiency and CETP inhibitors.
    Mabuchi H; Nohara A; Inazu A
    Mol Cells; 2014 Nov; 37(11):777-84. PubMed ID: 25410905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combined treatment: regimens, indications and safety profile].
    Muñiz Grijalvo O; Villar Ortiz J
    Clin Investig Arterioscler; 2013; 25(3):140-5. PubMed ID: 23880257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Becoming more "goal-oriented" in therapy of dyslipidemias: results of the Hungarian MULTI GAP 2010].
    Reiber I; Paragh G; Márk L; Pados G
    Orv Hetil; 2011 May; 152(21):822-7. PubMed ID: 21546340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia.
    Teramoto T; Takeuchi M; Morisaki Y; Ruotolo G; Krueger KA
    Am J Cardiol; 2014 Jun; 113(12):2021-9. PubMed ID: 24786356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dyslipidemia and PCSK9 inhibitors - practical focused update of indication and reimbursement criteria].
    Soška V
    Vnitr Lek; 2022; 68(3):191-194. PubMed ID: 36208951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging drugs for hyperlipidaemia: an update.
    Florentin M; Kostapanos MS; Kei A; Elisaf MS
    Expert Opin Emerg Drugs; 2014 Dec; 19(4):471-88. PubMed ID: 25356785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modern Management of Familial Hypercholesterolemia.
    Duell PB; Jialal I
    Metab Syndr Relat Disord; 2016 Dec; 14(10):463-467. PubMed ID: 27797643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular pathways and agents for lowering LDL-cholesterol in addition to statins.
    Costet P
    Pharmacol Ther; 2010 Jun; 126(3):263-78. PubMed ID: 20227438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.